Taliglucerase Alfa

What is Taliglucerase Alfa

Taliglucerase alfa is an enzyme used in the treatment of patients with Gaucher’s disease.

Taliglucerase alfa replaces the endogenous enzyme beta-glucocerebrosidase.

Taliglucerase alfa is produced by recombinant DNA technology using plant cell culture (carrot), making it the first plant-made pharmaceutical.

This process is beneficial because it eliminates the threat of viruses and other pathogens that can contaminate mammalian stocks.

Taliglucerase differs from the endogenous metabolic enzyme by two amino acids at the N terminal and up to 7 amino acids at the C terminal.

Treatment with taliglucerase alfa is indicated for adults and children >= 4 years with a confirmed diagnosis of Type I Gaucher’s disease. The FDA approved taliglucerase alfa under orphan status in May 2012.

Brand Name

ELELYSO

Indications

  • Gaucher disease

For replacement therapy of glucosylceramidase in confirmed (type 1) Gaucher disease

Side Effects

  1. abdominal pain
  2. anaphylactoid reactions
  3. angioedema
  4. antibody formation
  5. arthralgia
  6. back pain
  7. cough
  8. diarrhea
  9. dizziness
  10. erythema
  11. fatigue
  12. flushing
  13. headache
  14. hypotension
  15. infusion-related reactions
  16. nausea
  17. pruritus
  18. rash
  19. throat irritation
  20. urticaria
  21. vomiting
  22. wheezing

Monitoring Parameters

  • laboratory monitoring not necessary

Contraindications

  • breast-feeding
  • children
  • infants
  • infusion-related reactions
  • neonates
  • pregnancy

Interactions

There are no drug interactions associated with Taliglucerase Alfa products.

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top